A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives

European Journal of Cancer and Clinical Oncology

Volumn 25, Issue 4, 1989, Pages 711-720

  Voest, E E ^a   van Houwelingen, J C ^b   Neijt, J P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; MELPHALAN; METHOTREXATE; TREOSULFAN;

CORYNEBACTERIUM PARVUM; FEMALE; HUMAN; METASTASIS; OVARY CANCER; PROGNOSIS; REVIEW; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; HUMAN; META-ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; RISK;

EID: 0024541841     PISSN: 02775379     EISSN: None     Source Type: Journal    
DOI: 10.1016/0277-5379(89)90208-3     Document Type: Article

References (51)

1. Advanced ovarian adenocarcinoma, a prospective clinical trial of melphalan (L-PAM) vs. combination chemotherapy
2. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO stages III and IV) as measured by surgical endstaging (second-look operation)
3. Surgical resection of tumorbulk in the primary treatment of ovarian carcinoma
4. Prognostic importance of histologic grading in ovarian carcinoma
5. Advanced ovarian cancer
6. Tumor ploidy as a major of prognostic factor in advanced ovarian cancer
7. Prognostic factors in advanced ovarian carcinoma
8. Epithelial carcinoma of the ovary: prognostic importance of histologic grade
9. Primary secondary and meta-analysis of research
10. Meta-analysis of randomized controlled trials
11. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas
12. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs. CHAP-5) in advanced ovarian carcinoma
13. A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma
14. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin and cyclophosphamide in stage III–IV epithelial ovarian carcinoma
15. Combination chemotherapy for advanced ovarian cancer
16. Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF)
17. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus Adriamycin plus cyclophosphamide in ovarian carcinoma
18. Chemotherapy of advanced ovarian carcinoma: initial experience using a platinum-based combination
19. A prospective randomized clinical trail of melphalan and cis-platinum versus hexamethylmelamine, Adriamycin and cyclophosphamide in advanced ovarian cancer
20. Single agent Adriamycin followed by combination hexamethylmelamine-cyclophosphamide for advanced ovarian carcinoma
21. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide in advanced ovarian cancer
22. Cisplatin based combination chemotherapy for advanced ovarian cancer
23. Prospective study with Hexa-CAF combination in ovarian carcinoma
24. Continuous versus intermittent treatment with treosulfan in advanced ovarian cancer
25. Preliminary report of a clinical trial of the treatment of patients with advanced stage III and IV ovarian cancer with melphalan, 5-fluorouracil and methotrexate in combination and sequentially: a study of the clinical trials group of the National Cancer Institute of Canada
26. Advanced ovarian adenocarcinoma
27. Chemo-immunotherapy in the management of primary stage III ovarian cancer; a Gynecologic Oncology Group Study
28. The treatment of advanced ovarian carcinoma with high dose intravenous cyclophosphamide
29. Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer
30. Chemotherapy of advanced ovarian carcinoma: use of intravenous treosulfan in previously untreated disease
31. Cyclophosphamide plus cis-platinum in combination: treatment program for stage III and IV ovarian carcinoma
32. Improved chemotherapy for ovarian cancer with cis-diammine-dichloroplatinum and Adriamycin
33. Single agent cis-platinum therapy for advanced ovarian cancer
34. High-dose methotrexate with ‘rescue’ plus cyclophosphamide as initial chemotherapy in ovarian adenocarcinoma
35. Advanced ovarian cancer: 3 year-results of a 6–8 month, 2-drug cisplatin-containing regimen
36. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial
37. A randomized study of single agent versus combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma
38. Adriamycin and cisplatin in advanced ovarian cancer
39. Hexamethyl-melamine, Adriamycin and cyclophosphamide (HAC) versus cis-dichlorodiammine platinum, Adriamycin and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized trial
40. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma
41. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma
42. Alternating combination chemotherapy for stages III and IV ovarian carcinoma
43. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma
44. Treatment of advanced epithelial ovarian cancer using cisplatin, Adriamycin and cytoxan—the Indiana University experience
45. Advanced ovarian cancer: a prospective randomised trial of chlorambucil versus combined cyclophosphamide and cis-diamminedichloroplatinum
46. Hexamethylmelamine: an evaluation of its role in the treatment of ovarian cancer
47. Long-term results of combination chemotherapy in advanced ovarian cancer
48. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer
49. Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease
50. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma